Search results
Results from the WOW.Com Content Network
In Latin America, 2019 was a record-setting dengue fever outbreak, with more than 2.7 million cases and 1206 deaths during the first 10 months of 2019. [25] [26] As of 2023, cases and Deaths of dengue fever reached up to 3 million cases and 1302 deaths.
However around 10% of those 800,000 had not had dengue fever before and therefore are at risk of severe infection because of the vaccine. [2] In the Philippines, the Dengvaxia controversy has contributed to overall vaccine hesitancy because of heightened concerns about vaccine safety.
Dengue fever is a mosquito-borne disease caused by dengue virus, prevalent in tropical and subtropical areas. It is frequently asymptomatic ; if symptoms appear, they typically begin 3 to 14 days after infection.
This year, the incidence of dengue fever globally has been the highest on record, especially in Latin American countries, where more than 9.7 million dengue cases have been reported. That's twice ...
More than 12.6m cases were recorded this year, the region's UN health organisation says.
Reported cases of dengue in the Americas nearly tripled to a record high of over 12.6 million this year, including 21,000 severe cases and over 7,700 deaths, the Pan American Health Organization ...
Dengue vaccine is a vaccine used to prevent dengue fever in humans. [9] Development of dengue vaccines began in the 1920s but was hindered by the need to create immunity against all four dengue serotypes. [10] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga. [11] [12]
Around 4 billion people, or about half the world's population, live in areas with a risk of contracting dengue, according to data from the U.S. Centers for Disease Control and Prevention.